Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing.
Journal of Clinical Oncology.
Times cited: 64
A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer.
Times cited: 14